AI-discovered cellular morphometric biomarkers in needle biopsy of prostate cancer predict neoadjuvant androgen deprivation therapy response and enable therapeutic targeting of mTOR in androgen depriv
4 hours ago
- #Prostate Cancer
- #Artificial Intelligence
- #Precision Medicine
- AI model identifies 13 cellular morphometric biomarkers (CMBs) from prostate cancer needle biopsy images.
- The 13-CMB model predicts response to neoadjuvant androgen deprivation therapy (NADT) with high accuracy (AUC: 0.981).
- It stratifies patients into responders and non-responders across multiple independent cohorts, including TCGA-PRAD.
- The model correlates with pathologic complete response and biochemical recurrence-free survival in validation cohorts.
- CMBs provide independent prognostic value beyond established clinical factors and genomic biomarkers.
- The biomarkers predict molecular differences and suggest mTOR inhibitors may benefit non-responders, validated in organoids.